Back to Report Store Home

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

  • Published: Aug-2016
  • Report Code: GBIHC421MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 11

2.5 Diagnosis 14

2.6 Classification 15

2.7 Prognosis 16

2.8 Treatment Options 16

2.8.1 Treatment Algorithm 17

2.8.2 Non-insulin T2DM Therapies 18

2.8.3 Insulin T2DM Therapies 21

2.9 Treatment Segments 23

2.9.1 Non-insulin therapies 23

2.9.2 Insulin Therapies 38

2.10 Co-morbidities and Complications 41

3 Marketed Products 44

3.1 Overview 44

3.2 Biguanides 45

3.2.1 Metformin 45

3.3 Sulfonylureas 46

3.4 Thiazolidinediones 47

3.4.1 Pioglitazone 47

3.4.2 Duvie (lobeglitazone) – Chong Kun Dang 49

3.5 GLP-1 Receptor Agonists 49

3.5.1 Byetta (exenatide) – Eli Lilly 49

3.5.2 Bydureon (exenatide) – AstraZeneca 50

3.5.3 Victoza (liraglutide) – Novo Nordisk 51

3.5.4 Lyxumia (lixisenatide) – Sanofi 53

3.5.5 Tanzeum (albiglutide) – GlaxoSmithKline 54

3.6 DPP-4 Inhibitors 55

3.6.1 Januvia (sitagliptin) – Merck 55

3.6.2 Galvus (vildagliptin) – Novartis 57

3.6.3 Onglyza (saxagliptin) – Bristol-Myers Squibb/AstraZeneca 58

3.6.4 Trajenta (linagliptin) – Bristol-Myers Squibb/AstraZeneca 59

3.6.5 Zemiglo (gemigliptin) – LG Life Sciences 60

3.6.6 Suganon (evogliptin) – Dong-A ST 61

3.6.7 Gadret (anagliptin) – JW Pharmaceutical 61

3.6.8 Nesina (alogliptin) – Takeda 62

3.6.9 Tenelia (teneligliptin) – Mitsubishi Tanabe Pharma 63

3.7 SGLT-2 Inhibitors 63

3.7.1 Forxiga (dapagliflozin) – AstraZeneca 63

3.7.2 Invokana (canagliflozin) – Janssen 65

3.7.3 Jardiance (empagliflozin) – Boehringer Ingelheim 65

3.7.4 Suglat (ipragliflozin) – Astellas 66

3.8 Insulin Therapies 67

3.8.1 Lantus (insulin glargine) – Sanofi 67

3.8.2 Levemir (insulin detemir) – Novo Nordisk 68

3.8.3 Tresiba (insulin degludec) – Novo Nordisk 69

3.8.4 Toujeo (insulin glargine) – Sanofi 70

3.9 Comparative Efficacy and Safety of Marketed Products 71

4 Pipeline 74

4.1 Overview 74

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 75

4.3 Pipeline by Molecular Target 76

4.4 Promising Pipeline Candidates 80

4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) – Novo Nordisk 80

4.4.2 Trulicity (dulaglutide) 83

4.4.3 Ertugliflozin – Pfizer 85

4.4.4 Bexagliflozin – Theracos 86

4.4.5 Omarigliptin – Merck 88

4.5 Comparative Efficacy and Safety of Pipeline Products 90

4.6 Product Competitive Framework 90

5 Clinical Trial Analysis 94

5.1 Failure Rate 94

5.1.1 Overall Failure Rate 94

5.1.2 Failure Rate by Phase and Molecule Type 94

5.1.3 Failure Rate by Phase and Molecular Target 95

5.2 Clinical Trial Size 96

5.3 Clinical Trial Duration 100

5.3.1 Trial Duration by Stage of Development and Molecule Type 100

5.3.2 Trial Duration by Stage of Development and Molecular Target 102

5.4 Summary of Clinical Trial Metrics 102

6 Multi-Scenario Forecast 104

6.1 Geographical Markets 104

6.2 South-East Asia Markets 104

6.3 South Korea 107

6.3.1 Treatment Usage Patterns 107

6.3.2 Annual Cost of Therapy 107

6.3.3 Market Size 108

6.4 Singapore 109

6.4.1 Treatment Usage Patterns 109

6.4.2 Annual Cost of Therapy 110

6.4.3 Market Size 111

6.5 Taiwan 111

6.5.1 Treatment Usage Patterns 111

6.5.2 Annual Cost of Therapy 112

6.5.3 Market Size 113

6.6 Malaysia 114

6.6.1 Treatment Usage Patterns 114

6.6.2 Annual Cost of Therapy 115

6.6.3 Market Size 116

6.7 Philippines 116

6.7.1 Treatment Usage Patterns 116

6.7.2 Annual Cost of Therapy 117

6.7.3 Market Size 118

6.8 Thailand 118

6.8.1 Treatment Usage Patterns 118

6.8.2 Annual Cost of Therapy 119

6.8.3 Market Size 120

6.9 Vietnam 121

6.9.1 Treatment Usage Patterns 121

6.9.2 Annual Cost of Therapy 121

6.9.3 Market Size 122

6.10 Indonesia 123

6.10.1 Treatment Usage Patterns 123

6.10.2 Annual Cost of Therapy 124

6.10.3 Market Size 125

7 Market Dynamics, (Drivers and Barriers) 126

7.1 Drivers 126

7.1.1 Aging Population, Increasing Obesity and Growing Economy 126

7.1.2 Increasing Awareness of T2DM 126

7.1.3 Continued Uptake of Recently Approved Drug Classes 126

7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm 126

7.1.5 Enhanced Usage of Combination Therapies 126

7.2 Barriers 127

7.2.1 Non-pharmacological First-line Treatment 127

7.2.2 Widespread Usage of Generic Drugs 127

7.2.3 Poor Adherence to Treatment Regimens 127

7.2.4 Generic Erosion Resulting from Patent Expirations 127

8 Deals and Strategic Consolidations 128

8.1 Licensing Deals 128

8.1.1 Deals by Region and Value 128

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 129

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 130

8.1.4 Key Licensing Deals 132

8.2 Co-development Deals 133

8.2.1 Deals by Region and Value 133

8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 135

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 137

8.2.4 Key Co-Development Deals 139

9 Appendix 142

9.1 All Pipeline Drugs by Phase of Development 142

9.1.1 Discovery 142

9.1.2 Preclinical 145

9.1.3 IND/CTA-filed 153

9.1.4 Phase I 153

9.1.5 Phase II 155

9.1.6 Phase III 157

9.1.7 Pre-registration 158

9.2 Market Forecasts to 2022 159

9.2.1 South-East Asia 159

9.2.2 South Korea 159

9.2.3 Singapore 160

9.2.4 Taiwan 160

9.2.5 Malaysia 161

9.2.6 Philippines 161

9.2.7 Thailand 162

9.2.8 Vietnam 162

9.2.9 Indonesia 163

9.3 References 163

9.4 Abbreviations 174

9.5 Research Methodology 176

9.5.1 Secondary Research 176

9.5.2 Marketed Product Profiles 177

9.5.3 Late-Stage Pipeline Candidates 177

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 177

9.5.5 Pipeline Analysis 177

9.5.6 Forecasting Model 178

9.5.7 Deals Data Analysis 179

9.6 Contact Us 180

9.7 Disclaimer 180

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards